BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:From Ideas to Drugs
DTSTART:20181005T150000
DTEND:20181005T160000
DTSTAMP:20260414T181439Z
UID:3bd31fa286c5896f33f689758d8978154466f245668f47cae5bbd42d
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr Martine Clozel\nMartine Clozel will receive a degree honori
 s causa at the Magistrale. It was the opportunity to invite her for a uniq
 ue seminar at the School of life sciences.\n\nMartine Clozel\, a pediatric
 ian specializing in neonatal intensive care\, has an MD degree from Nancy 
 University\, France\, and received further training in physiology and phar
 macology from McGill University\, Montreal\, and the University of Califor
 nia\, San Francisco.\nDuring her 11 years at F. Hoffmann-La Roche Ltd\, sh
 e initiated the research project on endothelin and endothelin receptor ant
 agonists which led to the discovery and clinical development of bosentan (
 Tracleer®)\, tezosentan\, clazosentan and other molecules.\nShe has publi
 shed over 140 peer-reviewed papers in the fields of endothelial function\,
  endothelin and endothelin receptor antagonists. In 1997 she was awarded t
 he Hoffmann-La Roche Research Prize for her achievements in the field of e
 ndothelin research. In 2008\, she was honored as “Chevalier dans l’Ord
 re de la Légion d’Honneur”. In 2015\, she was awarded the Tomoh Masak
 i award for her contribution to endothelin science and  successfully disc
 overing several endothelin receptor antagonists\, especially Tracleer® (b
 osentan) and Opsumit® (macitentan)\, two molecules that each made history
  in the field of pulmonary arterial hypertension.\nIn 1997 Martine co-foun
 ded Actelion Pharmaceuticals Ltd\, where she was Senior Vice President\, C
 hief Scientific Officer and Head of Drug Discovery\, Pharmacology & Precli
 nical Development. Martine was also is a member of the Extended Actelion E
 xecutive Committee.\nWith the sale of Actelion to Johnson & Johnson in Jun
 e 2017\, the drug discovery and early clinical pipeline business was demer
 ged and Idorsia was established. Idorsia\, a new biopharmaceutical company
 \, is specialized in the discovery and development of small molecules to p
 rovide innovative therapeutic options. Martine retains her role as Chief S
 cientific Officer. Idorsia has currently 11 molecules in clinical developm
 ent.
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR